Cited by 148Pancreatic and Hepatic Oncology ResearchNeuroendocrine Tumor Research AdvancesCholangiocarcinoma and Gallbladder Cancer Studies

Development and Validation of a Multi-institutional Preoperative Nomogram for Predicting Grade of Dysplasia in Intraductal Papillary Mucinous Neoplasms (IPMNs) of the Pancreas: A Report from The Pancreatic Surgery Consortium

Open access
Attiyeh, Marc A., Fernández-del Castillo, Carlos, Al Efishat, Mohammad, Eaton, Anne A., Gönen, Mithat, Batts, Ruqayyah, Pergolini, Ilaria, Rezaee, Neda +12 more·2018·Annals of Surgery

Abstract

OBJECTIVE: Previous nomogram models for patients undergoing resection of intraductal papillary mucinous neoplasms (IPMNs) have been relatively small single-institutional series. Our objective was to improve upon these studies by developing and independently validating a new model using a large multiinstitutional dataset. SUMMARY BACKGROUND DATA: IPMNs represent the most common radiographically identifiable precursor lesions of pancreatic cancer. They are a heterogenous group of neoplasms in which more accurate markers of high-grade dysplasia or early invasive carcinoma could help avoid unnecessary surgery in 1 case and support potentially curative intervention (resection) in another. METHODS: Prospectively maintained databases from 3 institutions were queried for patients who had undergone resection of IPMNs between 2005 and 2015. Patients were separated into main duct [main and mixed-type (MD)] and branch duct (BD) types based on preoperative imaging. Logistic regression modeling was used on a training subset to develop 2 independent nomograms (MD and BD) to predict low-risk (low- or intermediate-grade dysplasia) or high-risk (high-grade dysplasia or invasive carcinoma) disease. Model performance was then evaluated using an independent validation set. RESULTS: We identified 1028 patients who underwent resection for IPMNs [MD: n = 454 (44%), BD: n = 574 (56%)] during the 10-year study period. High-risk disease was present in 487 patients (47%). Patients with high-risk disease comprised 71% and 29% of MD and BD groups, respectively (P <0.0001). MD and BD nomograms were developed on the training set [70% of total (n = 720); MD: n = 318, BD: n = 402] and validated on the test set [30% (n = 308); MD: n = 136, BD: n = 172]. The presence of jaundice was almost exclusively associated with high-risk disease (57 of 58 patients, 98%). Cyst size >3.0 cm, solid component/mural nodule, pain symptoms, and weight loss were significantly associated with high-risk disease. C-indices were 0.82 and 0.81 on training and independent validation sets, respectively; Brier scores were 0.173 and 0.175, respectively. CONCLUSIONS: For patients with suspected IPMNs, we present an independently validated model for the prediction of high-risk disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/sla.0000000000002015

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The Pancreatic Surgery Consortium's logistic regression model based on patient characteristics and IPMN imaging features showed significant stratification between low-risk and high-risk groups for recurrence of high-grade dysplasia or invasive cancer.

    “Their logistic regression model to assess the risk of high-grade dysplasia or invasive carcinoma was based on patient characteristics and IPMN imaging features and showed significant stratification between low-risk and high-risk groups.160”

    From Artificial Intelligence and Early Detection of Pancreatic Cancer: 2020 Summative Review (2021) · cites this paper as [160]

    Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Attiyeh, M. A., Fernández-del Castillo, C., Al Efishat, M., Eaton, A. A., Gönen, M., Batts, R., Pergolini, I., Rezaee, N., Lillemoe, K. D., Ferrone, C. R., Mino-Kenudson, M., Weiss, M. J., Cameron, J. L., Hruban, R. H., D’Angelica, M. I., DeMatteo, R. P., Kingham, T. P., Jarnagin, W. R., Wolfgang, C. L., & Allen, P. J.
Affiliations
  • Memorial Sloan Kettering Cancer Center (US)
  • Harvard University (US)
  • Johns Hopkins University (US)
  • Massachusetts General Hospital (US)
Corresponding author
  • Attiyeh, Marc A.
  • Batts, Ruqayyah
  • DeMatteo, Ronald P.
  • Kingham, T. Peter
  • Jarnagin, William R.
  • Allen, Peter J.
Venue
Annals of Surgery
Published
2018-01
Volume
267
Issue
1
Pages
157-163
ISSN
0003-4932 (ISSN-L)
OpenAlex
W2522795941
Cited by
146
References
21
Citations by year
2026: 16 · 2025: 13 · 2024: 17 · 2023: 18 · 2022: 14 · 2021: 21 · 2020: 21 · 2019: 13 · 2018: 9 · 2017: 4
FWCI
4.67
Type
journal article
Language
en
Open access
Locations
  • Annals of Surgery (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Cancer Institute (R01CA182076, P30CA008748)
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Health Sciences › Medicine › Epidemiology › Neuroendocrine Tumor Research Advances
  • Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
Keywords
intraductal papillary mucinous neoplasm, pancreatic IPMN, high-grade dysplasia, invasive carcinoma, preoperative nomogram, pancreatic resection, main duct IPMN, branch duct IPMN, jaundice, cyst size, solid component, risk prediction, pancreatic cancer precursor lesions, multi-institutional validation, prognostic factors, avoiding unnecessary surgery, weight loss
MeSH terms
Adolescent, Adult, Aged, Aged, 80 and over, Adenocarcinoma, Mucinous, Carcinoma, Papillary, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Invasiveness, Neoplasm Staging, Pancreatectomy, Pancreatic Neoplasms, Predictive Value of Tests, Prospective Studies, Retrospective Studies, ROC Curve, Carcinoma, Pancreatic Ductal, Nomograms, Young Adult, Preoperative Period

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review